Dimed Distribuidora de Medicamentos (PNVL3) Stock Overview
Sells medicines, perfumeries, personal hygiene and beauty products, cosmetics and dermocosmetics in Brazil. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for PNVL3 from our risk checks.
PNVL3 Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Dimed S.A. Distribuidora de Medicamentos Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R$14.55 |
| 52 Week High | R$16.57 |
| 52 Week Low | R$8.06 |
| Beta | 0.55 |
| 1 Month Change | 2.25% |
| 3 Month Change | 17.43% |
| 1 Year Change | 63.48% |
| 3 Year Change | 48.02% |
| 5 Year Change | -25.95% |
| Change since IPO | 286,148.28% |
Recent News & Updates
Recent updates
Shareholders Can Be Confident That Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Earnings Are High Quality
Mar 27
Why Investors Shouldn't Be Surprised By Dimed S.A. Distribuidora de Medicamentos' (BVMF:PNVL3) 26% Share Price Surge
Feb 12What You Can Learn From Dimed S.A. Distribuidora de Medicamentos' (BVMF:PNVL3) P/E
Dec 19Does Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Deserve A Spot On Your Watchlist?
Nov 29Capital Allocation Trends At Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Aren't Ideal
Jun 20
Digital Strategy And AI Investments Will Improve Efficiency In Pharma Retail
Panvel's digital strategy and investment in AI tools boost sales and improve margins through increased efficiencies and tech-savvy customer engagement.Dimed S.A. Distribuidora de Medicamentos Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Nov 17Investors Could Be Concerned With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Returns On Capital
Nov 04These 4 Measures Indicate That Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Using Debt Extensively
Jul 12Investors Shouldn't Be Too Comfortable With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Robust Earnings
May 27Be Wary Of Dimed Distribuidora de Medicamentos (BVMF:PNVL3) And Its Returns On Capital
Apr 15Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Seems To Use Debt Quite Sensibly
Mar 25The Returns On Capital At Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Don't Inspire Confidence
Jan 06Dimed S.A. Distribuidora de Medicamentos' (BVMF:PNVL3) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors
Oct 23Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Reinvesting At Lower Rates Of Return
Aug 15Shareholder Returns
| PNVL3 | BR Consumer Retailing | BR Market | |
|---|---|---|---|
| 7D | -2.5% | -2.2% | -1.1% |
| 1Y | 63.5% | 2.8% | 33.5% |
Return vs Industry: PNVL3 exceeded the BR Consumer Retailing industry which returned 2.7% over the past year.
Return vs Market: PNVL3 exceeded the BR Market which returned 34% over the past year.
Price Volatility
| PNVL3 volatility | |
|---|---|
| PNVL3 Average Weekly Movement | 4.9% |
| Consumer Retailing Industry Average Movement | 5.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in BR Market | 8.5% |
| 10% least volatile stocks in BR Market | 1.7% |
Stable Share Price: PNVL3 has not had significant price volatility in the past 3 months compared to the BR market.
Volatility Over Time: PNVL3's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1920 | 11,282 | Julio Mottin Neto | www.grupopanvel.com.br |
Dimed S.A. Distribuidora de Medicamentos sells medicines, perfumeries, personal hygiene and beauty products, cosmetics and dermocosmetics in Brazil. It sells its products through physical stores in retail industry. Dimed S.A.
Dimed S.A. Distribuidora de Medicamentos Fundamentals Summary
| PNVL3 fundamental statistics | |
|---|---|
| Market cap | R$2.16b |
| Earnings (TTM) | R$124.61m |
| Revenue (TTM) | R$5.51b |
Is PNVL3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PNVL3 income statement (TTM) | |
|---|---|
| Revenue | R$5.51b |
| Cost of Revenue | R$3.68b |
| Gross Profit | R$1.83b |
| Other Expenses | R$1.70b |
| Earnings | R$124.61m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.84 |
| Gross Margin | 33.17% |
| Net Profit Margin | 2.26% |
| Debt/Equity Ratio | 55.5% |
How did PNVL3 perform over the long term?
See historical performance and comparisonDividends
Does PNVL3 pay a reliable dividends?
See PNVL3 dividend history and benchmarks| Dimed Distribuidora de Medicamentos dividend dates | |
|---|---|
| Ex Dividend Date | Mar 27 2025 |
| Dividend Pay Date | Apr 30 2026 |
| Days until Ex dividend | 388 days |
| Days until Dividend pay date | 11 days |
Does PNVL3 pay a reliable dividends?
See PNVL3 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/18 14:32 |
| End of Day Share Price | 2026/04/17 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dimed S.A. Distribuidora de Medicamentos is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Marcio Osako | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |
| Francisco Navarrete | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |
| Frederico Mendes | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |